Preliminary success in the characterization and management of a sudden breakout of a novel H7N9 influenza A virus

International Journal of Biological Sciences

Volumn 10, Issue 1, 2014, Pages 109-118

  Wu, Yan Ling ^a   Shen, Li Wen ^b   Ding, Yan Ping ^a,b   Tanaka, Yoshimasa ^c   Zhang, Wen ^b  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Avian influenza A; Diagnosis; H7N9 virus; Infection; Prevention; Treatment

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ANIMAL; AVIAN INFLUENZA; AVIAN INFLUENZA A; BIRD; CHINA; DIAGNOSIS; EPIDEMIC; GENETIC REASSORTMENT; GEOGRAPHY; H7N9 VIRUS; HUMAN; INFECTION; INFLUENZA; INFLUENZA VIRUS A H7N9; PHYLOGENY; PREVENTION.; REVIEW; TREATMENT; TREATMENT OUTCOME; VIROLOGY;

AVIAN INFLUENZA A; DIAGNOSIS; H7N9 VIRUS; INFECTION; PREVENTION.; TREATMENT;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; CHINA; DISEASE OUTBREAKS; GEOGRAPHY; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PHYLOGENY; REASSORTANT VIRUSES; TREATMENT OUTCOME;

EID: 84892401755     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.8198     Document Type: Review

References (114)

1. Wen Y, Klenk HD. H7N9 avian influenza virus-search and re-search. Emerg Microbes Infect. 2013; 2: e18. doi: 10. 1038/emi. 2013. 18.
2. [Internet] World Health Organization (WHO). Number of confirmed human cases for influenza A(H7N9) reported to WHO. http://www. who. int/influenza/human_animal_interface/influenza_h7n9/0 1_ReportWebH7N9Number. pdf.
3. [Internet] National Health and Family Planning Commission of China (NHFPC): Shanghai, Anhui occurred three cases of human infection with H7N9 avian influenza confirmed cases. http://www. moh. gov. cn/mohwsyjbgs/s3578/201303/44f25bd6bed14cf082512d8b6258fb3d. shtml.
4. Arima Y, Zu R, Murhekar M, et al. Human infections with avian influenza A(H7N9) virus in China: preliminary assessments of the age and sex distribution. WPSAR. 2013; doi: 10. 5365/wpsar. 2013. 4. 2. 005.
5. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A(H7N9) virus infections. N Engl J Med. 2013; 368(20): 1862-4.
6. Jonges M, Meijer A, Fouchier RA, et al. Guiding outbreak management by the use of influenza A(H7Nx) virus sequence analysis. Euro Surveill. 2013; 18(16): 20460.
7. Fouchier RA, Kawaoka Y, Cardona C, et al. Gain-of-Function experiments on H7N9. Science. 2013; 341: 612-3.
8. [Internet] World Health Organization (WHO): Number of confirmed human cases for influenza A(H7N9) reported to WHO. http://www. who. int/influenza/human_animal_interface/influenza_h7n9/0 9_ReportWebH7N9Number. pdf.
9. Ke Y, Wang Y, Liu S, et al. High severity and fatality of human infections with avian influenza A(H7N9) infection in China. Clin Infect Dis. 2013; doi: 10. 1093/cid/cit371.
10. Xu C, Havers F, Wang L, et al. Monitoring avian influenza A(H7N9) virus through National Influenza-like illness Surveillance, China. Emerg Infect Dis. 2013; 19(8): 1289-92.
11. Yu H, Cowling BJ, Feng L, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet. 2013; 382(9887): 138-45.
12. Li Q, Zhou L, Zhou M, et al. Preliminary report: epidemiology of the avian influenza A(H7N9) outbreak in China. N Engl J Med. 2013; doi: 10. 1056/NEJMoa1304617.
13. Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013; 341(6144): 410-4.
14. Cowling BJ, Freeman G, Wong JY, et al. Preliminary inferences on the age-specific seriousness of human disease caused by avian influenza A(H7N9) infections in China, March to April 2013. Euro Surveill. 2013; 18(19): 20475.
15. Cowling BJ, Jin L, Lau EHY, et al. Comparative epidemiology of human infections with avian influenza AH7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 2013; 382(9887): 129-37.
16. [Internet] Latest news about human infection with influenza A(H7N9) Virus. http://roll. news. sina. com. cn/s_qlg2013_all/1/index. shtml.
17. Guan Y, Farooqui A, Zhu H, et al. H7N9 incident, immune status, the elderly and a warning of an influenza pandemic. J Infect Dev Ctries. 2013; 7(4): 302-7.
18. Bermejo-Martin JF, Almansa R, Lejarazu RO, et al. Weakened immunity in aged hosts with comorbidities as a risk factor for the emergence of influenza A H7N9 mutants. J Infect Dev Ctries. 2013; 7(6): 497-8.
19. Zhang Q, Wang S, Wu M, et al. Epidemiological and risk analysis of the H7N9 subtype influenza outbreak in China at its early stage. Chin Sci Bull. 2013; doi: 10. 1007/s11434-013-5880-5.
20. Zhu H, Wang D, Kelvin DJ, et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science. 2013; 341(6142): 183-6.
21. Qi X, Qian Y, Bao C, et al. Probable person to person transmission of novel avian influenza A(H7N9) virus in eastern China. BMJ. 2013; 347: f4752.
22. Liu D, Shi W, Shi Y, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analysis. Lancet. 2013; 381(9881): 1926-32.
23. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A(H7N9) virus. N Engl J Med. 2013; 368(20): 1888-97.
24. Ranst M, Lemey P. Genesis of avian-origin H7N9 influenza A viruses. Lancet 2013; 381(9881): 1883-5.
25. Wu A, Su C, Wang D, et al. Sequential reassortments underlie diverse influenza H7N9 genotypes in China. Cell Host Microbe. 2013; dx. doi. org/10. 1016/j. chom. 2013. 09. 001.
26. Zhang L, Zhang Z, Weng Z. Rapid reassortment of internal genes in avian influenza A H7N9 virus. Clin Infect Dis. 2013; doi: 10. 1093/cid/cit414.
27. Bao C, Cui L, Zhou M, et al. Live-animal markets and influenza A(H7N9) virus infection. N Engl J Med. 2013; 368(24): 2337-9.
28. Zhang B, Huang K, Guo J. Origin and the recombinant model of H7N9 virus prevailing in China. Nan Fang Yi Ke Da Xue Xue Bao. 2013; 33(7): 1017-21.
29. Kageyama T, Fujisaki S, Takashita E, et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill. 2013; 18(15): pii=20453.
30. Li J, Yu X, Pu X, et al. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. Sci China Life Sci. 2013; 56(6): 485-92.
31. Wang W, Lu B, Zhou H, et al. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol. 2010; 84(13): 6570-7.
32. Zhang Y, Zhang Q, Gao Y, et al. Key molecular factors in hemagglutinin and PB2 contribute to efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol. 2012; 86(18): 9666-74.
33. Chen Z, Zhou H, Kim L, et al. The receptor binding specificity of the live attenuated influenza H2 and H6 vaccine viruses contributes to vaccine immunogenicity and protection in ferrets. J Virol. 2012; 86(5): 2780-6.
34. Naeve C, Hinshaw V, Webster R. Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. J Virol. 1984; 51(2): 567-9.
35. Herfst S, Schrauwen E, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012; 336(6088): 1534-41.
36. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012; 486(7403): 420-8.
37. Tharakaraman K, Jayaraman A, Raman R, et al. Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. Cell. 2013; 153(7): 1486-93.
38. Han J, Niu F, Jin M, et al. Clinical presentation and sequence analyses of HA and NA antigens of the novel H7N9 viruses. Emerg Micro Infect. 2013; 2: e23; doi: 10. 1038/emi. 2013. 28.
39. Xiong C, Zhang Z, Jiang Q, et al. Evolutionary characteristics of A/Hangzhou/1/2013 and source of avian influenza virus H7N9 subtype in China. Clin Infect Dis. 2013; doi: 10. 1093/cid/cit294.
40. Matrosovich MN, Matrosovich TY, Gray T, et al. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci USA. 2004; 101(13): 4620-4.
41. Srinivasan K, Raman R, Jayaraman A, et al. Quantitative description of glycan-receptor binding of influenza A virus H7 hemagglutinin. PLoS One. 2013; 8(2): 49597.
42. Liu Q, Lu L, Sun Z, et al. Genomic signature and protein sequence analysis of a novel influenza A(H7N9) virus that causes an outbreak in humans in China. Microbes Infect. 2013; 15: 432-9.
43. Chen G, Lai MMC, Wu S, et al. Is avian influenza A(H7N9) virus staggering its way to humans? J Formos Med Assoc. 2013; 112(6): 312-8.
44. Xu W, Sun Z, Liu Q, et al. PA-356R is a unique signature of the avian influenza A(H7N9) viruses with bird-to-human transmissibility: potential implication for animal surveillances. J Infect. 2013; doi: 10. 1016/j. jinf. 2013. 08. 001.
45. Yen H, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio. 2013; 4(4): e00396-13. doi: 10. 1128/mBio. 00396-13.
46. Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A(H7N9) virus. Nature. 2013; 499(7459): 500-3.
47. Xiong X, Martin SR, Haire LF, et al. Receptor binding by an H7N9 influenza virus from humans. Nature. 2013; 499(7459): 496-499.
48. Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A(H7N9) virus in ferrets and mice. Nature. 2013; doi: 10. 1038/nature12391.
49. Rogers GN, Paulson JC, Daniels RS, et al. Single amino acid substitutions in influenza haemagglutin in change receptor binding specificity. Nature. 1983; 304(5921): 76-78.
50. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterization of viral genome. Lancet. 2013; 381(9881): 1916-25.
51. Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013; doi: 0. 1038/nature12392.
52. Wei Hu. Receptor binding specificity and sequence comparison of a novel avian-origin H7N9 virus in China. J Biomed Sci Eng. 2013; 6: 533-42.
53. Shi Y, Zhang W, Wang F, et al. Structures and Receptor Binding of Hemagglutinins from Human-Infecting H7N9 Influenza Viruses. Science. 2013; doi: 10. 1126/science. 1242917.
54. Hatta M, Gao P, Halfmann P, et al. Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001; 293(5536): 1840-2.
55. Munster VJ, de Wit E, van Riel D, et al. The molecular basis of the pathogenicity of the dutch highly pathogenic human influenza A H7N7 viruses. J Infect Dis. 2007; 196(2): 258-65.
56. Gao H, Lu H, Cao B, et al. Clinical findings in 111 cases of influenza A(H7N9) virus infection. N Engl J Med. 2013; 368(24): 2277-85.
57. Wu S, Wu F, He J. Emerging risk of H7N9 influenza in China. Lancet. 2013; 381(9877): 1539-40.
58. Arden KE, Mackay IM. Avian influenza A(H7N9) virus: can it help us more objectively judge all respiratory viruses? J Clin Virol. 2013; 58(1): 388-9.
59. Tang R, Chen H. An overview of the recent outbreaks of the avian-origin influenza A (H7N9) virus in the human. J Chin Med Assoc. 2013; 76(5): 245-8.
60. Shen P, Zong Y, Shu J, et al. Dynamic assessment of lung injury by ultrasound in a case with H7N9 inluenza. Crit Care. 2013; 17(3): 438.
61. Liu X, Li T, Zheng Y, et al. Poor responses to oseltamivir treatment in a patient with influenza A(H7N9) virus infection. Emerg Microbes Infect. 2013; 2: e27; doi: 10. 1038/emi2013. 30.
62. Cao B. What clinicians should know to fight against the novel avian-origin influenza A (H7N9) virus? Chin Med J. 2013; 126(12): 2205-6.
63. [Internet] National Health and Family Planning Commission of China (NHFPC). The diagnosis and treatment scheme of human infection with H7N9 avian influenza (Version 2, 2013). http://www. moh. gov. cn/ewebeditor/uploadfile/2013/04/20130410212136993. doc.
64. Wang Q, Yao K. A (H5N1) and A(H7N9) avian influenza: the H7N9 avian influenza outbreak in 2013. Chin J Contemp Pediatr. 2013; 15(6): 401-4.
65. Chang S, Lin P, Tsai JC, et al. The first case of H7N9 influenza in Taiwan. Lancet. 2013; 381(9878): 1621.
66. Lo Y, Chen W, Huang W, et al. Surveillance of avian influenza A(H7N9) virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013. Euro Surveill. 2013; 18(20): pii=20479.
67. [Internet] World Health Organization (WHO). Real-time RT-PCR protocol for the detection of A-vian influenza A (H7N9) virus. http://www. who. int/entity/influenza/gisrs_laboratory/cnic_realtime_rt_pc r_protocol_a_h7n9. pdf.
68. [Internet] World Health Organization (WHO). Serological detection of avian influenza A (H7N9) virus infections by turkey heamagglutination-inhibition assay. http://www. who. int/influenza/gisrs_laboratory/cnic_serological_diagnosis_hai_a_h7n9. pdf.
69. [Internet] World Health Organization (WHO). Serological detection of avian influenza A(H7N9) infections by microne utralization assay. http://www. who. int/influenza/gisrs_laboratory/cnic_serological_diagnosis_microneutralization_a_h7n9. pdf.
70. Corman VM, Eickmann M, Landt O, et al. Specific detection by real-time reverse-transcription reaction assays of a novel avian influenza A(H7N9) strain associated with human spillover infections in China. Euro Surveill. 2013; 18(16): 20461.
71. Baas C, Barr IG, Fouchier RA, et al. A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. Euro Surveill. 2013; 18(21): 20487.
72. Nie K, Zhao X, Ding X, et al. Visual detection of human infection with influenza A(H7N9) virus by subtype-specific reverse transcription loop-mediated isothermal amplification with hydroxynaphthol blue dye. Clin Microbiol Infect. 2013; 19(8): E372-5.
73. Ge Y, Wu B, Qi X, et al. Rapid and sensitive detection of novel avian-origin influenza A(H7N9) virus by reverse transcription Loop-Mediated Isothermal Amplification combined with a Lateral-Flow device. PLoS one. 2013; 8(8): e69941.
74. [Internet] European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: severe respiratory disease associated with a novel influenza A virus, A (H7N9) China. http://www. ecdc. europa. eu/en/publications/publications/ah7n9-china-rapid-risk-assessment. pdf.
75. World health organization (WHO): Frequently asked questions on human infection with influenza A (H7N9) virus. http://www. who. int/influenza/human_animal_interface/faq_H7N9/en/.
76. Chan PK, Lee N, Zaman M et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012; 206(9): 1359-66.
77. Yang S, Cao B, Liang L, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One. 2013; 7(1): e29652. doi: 10. 1371/journal. pone. 0029652.
78. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013; 381(9885): 2273-9.
79. Noah DL, Noah JW. Adapting global influenza management strategies to address emerging viruses. Am J Physiol Lung Cell Mol Physiol. 2013; 305(2): 108-17.
80. Qin G, Yu K, Shi T, et al. How does influenza virus a escape from amantadine? J Phys Chem B. 2010; 114(25): 8487-93.
81. Bernstein HH. As seasonal influenza wanes, be aware of H7N9. AAP News. 2013; doi: 10. 1542/aapnew. 20130426-1.
82. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the influenza resistance information study (IRIS). Clin Infect Dis. 2013; 56(9): 1197-205.
83. Kar P, Knecht V. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase. J Phys Chem B. 2012; 116(21): 6137-49.
84. Hay AJ, Hayden FJ. Oseltamivir resistance during treatment of H7N9 infection. Lancet. 2013; 381(9885): 2230-2.
85. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci Lond. 1998; 94(6): 557-72.
86. Confalonieri M, Kodric M, Santagiuliana M, et al. To use or not to use corticosteroids for pneumonia? A clinician's perspective. Monaldi Arch Chest Dis. 2012; 77(2): 94-101.
87. Bermejo-Martin JF, Almansa R, Lejarazu RO, et al. Weakened immunity in aged hosts with comorbidities as a risk factor for the emergence of influenza A H7N9 mutants. J Infect Dev Ctries. 2013; 7(6): 497-8.
88. Lu S, Xi X, Zheng Y, et al. Analysis of the clinical characteristics and treatment of two patients with avian influenza virus (H7N9). BioSci Trends. 2013; 7(2): 109-12.
89. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(1): 1-24.
90. Lee SM, Yen HL. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res. 2012; 96(3): 391-404.
91. Sailen B. New treatments for influenza. BMC Medicine. 2012; 10: 104.
92. Liu Q, Liu DY, Yang ZQ. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin. 2013; 34(10): 1257-69.
93. Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses. 2013; 7 (Suppl. 1): 63-75.
94. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013; 99(3): 417-35.
95. Eyer L, Hruska K. Antiviral agents targeting the influenza virus: a review and publication analysis. Veterinarni Medicina. 2013; (3): 113-185.
96. Edinger TO, Pohl MT, Stertz S. Entry of influenza A virus: host factors and antiviral targets. J Gen Virol. 2013; doi: 10. 1099/vir. 0. 059477-0.
97. [Internet] http://www. clinicaltrials. gov.
98. [Internet] World Health Organization (WHO). Vaccine response to the avian influenza A (H7N9) outbreak. http://www. who. int/influenza/vaccines/virus/CandidateVaccineVirusesH7N9_02May13. pdf.
99. Couch RB, Patel SM, Wade-Bowers CL, et al. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012; 7(12): e49704. doi: 10. 1371/journal. pone. 0049704119.
100. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER. C6 cell grown influenza H7 virus vaccine. Vaccine. 2009; 27(13): 1889-97.
101. De Groot AS, Ardito M, Terry F, et al. Low immunogenicity predicted for emerging avian-origin H7N9. Hum Vaccin Immunother. 2013; 9(5): 1-7.
102. Riedmann EM. Human vaccines & immunotherapeutics: news. Hum Vaccin Immunother. 2013; 9(6): 1187.
103. Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013(H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012(H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013.
104. Fries LF, Smith GE, Glenn GM. A Recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013; 13.
105. Song H, Wittman V, Byers A, et al. In vitro stimulation of human influenza specific CD8+ Tcells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine, 2010; 28(34): 5524-32.
106. Ahmad A, Krumkamp R, Reintjes R. Controlling SARS: a review on China's response compared with other SARS-affected countries. Trop Med Int Health. 2009; 14: 36-45.
107. From SARS to H7N9: will history repeat itself? Lancet. 2013; 381(9875): 1333.
108. Mei L, Song P, Tang Q, et al. Changes in and shortcomings of control strategies, drug stockpiles, and vaccine development during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans. BioSci Trends. 2013; 7(2): 64-76.
109. [Internet] National Health and Family Planning Commission of China (NHFPC). National Health and Family Planning Commission deploy prevention and control work about human infection with the A/H7N9 avian influenza. http://www. moh. gov. cn/wsb/pxwfb/201304/99a9ebd290dd4e86a388fff667 9c45df. shtml.
110. [Internet] National Health and Family Planning Commission of China (NHFPC). Notice of strengthen epidemic prevention and control for human infection with H7N9 avian influenza. http://www. moh. gov. cn/zhuzhan/wsbmgz/201307/56b09d2fa50e4a518b5a 83d8defac4f9. shtml.
111. Han J, Jin M, Zhan P, et al. Epidemiological link between exposure to poultry and all influenza A (H7N9) confirmed cases in Huzhou city, China, March to May 2013. Euro Surveill. 2013; 18(20): 20481.
112. Xu J, Lu S, Wang H, et al. Reducing exposure to avian influenza H7N9. Lancet. 2013; 381: 1815-6.
113. Murhekar M, Arima Y, Horby P, et al. Avian influenza A (H7N9) and the closure of live bird markets. WPSP. 2013; doi: 10. 5365/wpsar. 2013. 4. 2. 008.
114. Shaman J, Kohn M. Absolute humidity modulates influenza survival, transmission, and seasonality. PNAS. 2009; 106(10): 3645-6.